title: Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus.
abstract: BACKGROUND
  Infection is known to play a role in type 1 diabetes, but there is a paucity of information on its role in diabetes mellitus type 2. We examined the seroprevalence of selected viruses in a group of predominantly Hispanic patients with type 2 diabetes and control subjects without diabetes.
  
  
  METHODS
  One hundred thirteen patients, 83 with type 2 diabetes and 30 control subjects, all undergoing hemodialysis at the same facility in San Antonio, Texas, were tested for antibodies against coxsackie B viruses, cytomegalovirus (CMV), and parvovirus. Sixty-six of these patients and 25 control subjects were tested bimonthly for 6 months.
  
  
  RESULTS
  We observed a greater seroprevalence of anti-CMV IgG antibodies among patients with diabetes (97.6%), compared with control subjects (86.7%), and the difference was statistically significant [OR = 6.2, 95% CI: 1.1 to 36.0, P < 0.05]. Three draws on a subset of 91 patients produced still greater odds [OR = 12.4, 95% CI: 1.3 to 117, P < 0.05]. There were significantly more (P < or = 0.001) vascular complications among patients with diabetes. There was a colinearity of trends between diabetes, seropositivity to CMV, and age.
  
  
  CONCLUSIONS
  Our findings indicated an up to 12 times greater odds of having type 2 diabetes for persons previously exposed to CMV. Since accelerated atherosclerosis is also associated with diabetes and CMV, past CMV infection may be a common factor that links atherosclerosis and diabetes. No other viruses tested in this study, either coxsackie B viruses or parvovirus, showed a significant association with type 2 diabetes.
authors.affiliation: School of Public Health, University of Texas, Houston, TX, USA
authors.forename: Bertram W
authors.initials: BW
authors.lastname: Roberts
authors.forename: Irina
authors.initials: I
authors.lastname: Cech
mesh_terms: D000914:Antibodies, Viral / Q000302:isolation & purification*; D016022:Case-Control Studies; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000821:virology; D029822:Enterovirus B, Human / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D017058:Mexican Americans; D008875:Middle Aged; D016732:Parvovirus B19, Human / Q000276:immunology*; D016036:Seroepidemiologic Studies; D013781:Texas / Q000453:epidemiology
chemical_list: D000914:Antibodies, Viral